ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
BMS’ CAR T therapy Abecma moves closer toward EU approval pharmatimes
June 29, 2021Bristol Myers Squibb’s (BMS) CAR T cell therapy Abecma has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending its approval for the treatment of relapsed and ... -
Ide-cel provides lasting remissions in multiply-relapsed myeloma europeanpharmaceuticalreview
February 26, 2021BMS and bluebird bio have applied to the FDA for approval of ide-cel as a standard therapy for relapsed or refractory multiple myeloma based on positive Phase II trial results.
Pharma Sources Insight January 2025
